Maravai LifeSciences Holdings, Inc. MRVI Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 29.3%-8.0pp | 18.3%-23.5pp | 21.1%-25.2pp | 30.5%-15.3pp | 37.3%-6.7pp | |
| Operating margin | -82.2%+27.8pp | -115.9%-25.0pp | -100.9%-26.8pp | -145%-125pp | -109.9%-90.6pp | |
| Net margin | -51.1%+16.2pp | -70.4%-14.5pp | -62.9%+18.4pp | -87.6%-38.7pp | -67.3%-19.5pp | |
| EBITDA margin | -57.7%+31.8pp | -88.2%-15.9pp | -74.2%-17.0pp | -122.2%-119pp | -89.5%-85.9pp | |
| Free cash flow margin | -25.7%— | -38.1%— | -34.5%— | —— | —— | |
| Returns | ||||||
| Return on equity | -40.8%+4.9pp | -48.6%-9.6pp | -41%+11.1pp | -55%-26.8pp | -45.8%-17.6pp | |
| Return on assets | -12.5%+1.0pp | -14.7%-3.1pp | -11.4%+1.3pp | -16.4%-9.2pp | -13.5%-6.6pp | |
| Return on invested capital | -51.1%+19.5pp | -58.2%-1.6pp | -55.7%-32.4pp | -80.7%-75.1pp | -70.5%-64.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | |
| Inventory turnover | 3.2×+0.2× | 3.4×+0.4× | 3.2×+0.2× | 3.2×+0.1× | 3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5.9×-0.1× | 6.6×-0.9× | 5.3×-5.4× | 5.2×-4.8× | 6×-5.4× | |
| Quick ratio | 5×-0.2× | 5.7×-1.0× | 4.6×-5.3× | 4.5×-4.7× | 5.2×-5.3× | |
| Cash ratio | 3.9×-0.6× | 4.8×-0.8× | 4×-5.1× | 3.9×-4.5× | 4.5×-5.0× | |
| Leverage | ||||||
| Debt-to-equity | 1.3×+0.2× | 1.7×+0.6× | 1.5×-0.1× | 1.4×+0.1× | 1.1×-0.3× | |
| Debt-to-assets | 0.4×0.0× | 0.5×+0.1× | 0.4×0.0× | 0.4×0.0× | 0.3×0.0× | |
| Interest coverage | -6.5×-0.4× | -8×-3.0× | -6.1×-2.2× | -8.3×-7.2× | -6.1×-4.9× | |
| Per Share | ||||||
| Book value per share | $1.44-31.1% | $1.47-37.6% | $1.70-30.4% | $1.84-42.4% | $2.10-32.5% | |
| Valuation | ||||||
| Market capitalization | $849.64M+186% | $471.32M-39.0% | $415.23M-80.7% | $321.07M-82.2% | $317.47M-85.5% | |
| Enterprise value | $954.59M+182% | $619.14M-25.2% | $539.59M-74.7% | $422.24M-76.4% | $359.07M-83.6% | |
| Price / sales | 4.2×+2.9× | 2.5×-0.4× | 2.2×-5.6× | 1.5×-5.1× | 1.3×-6.7× | |
| Price / book | 4×+3.0× | 2.2×-0.2× | 1.7×-4.5× | 1.2×-2.9× | 1.1×-4.3× | |
| EV / sales | 4.7×+3.3× | 3.3×+0.1× | 2.8×-4.9× | 1.9×-4.6× | 1.5×-6.5× | |
| Free cash flow yield | -6.2%— | -15%— | -16%— | —— | —— | |
| Earnings yield | -12.3%+42.6pp | -27.7%-9.0pp | -29.1%-18.7pp | -60%-52.5pp | -51.3%-45.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Maravai LifeSciences Holdings, Inc.'s profit margins?
- Maravai LifeSciences Holdings, Inc. (MRVI) runs a 29.3% gross margin and a -82.2% operating margin, with a -51.1% net margin.
- Where do Maravai LifeSciences Holdings, Inc.'s ratios come from?
- Every ratio is computed from Maravai LifeSciences Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
